The AstraZeneca PLC ADR AZN advanced 2.35% to $73.92 Thursday, on what proved to be an all-around grim trading session for ...

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...

Bearish flow noted in AstraZeneca (AZN) with 10,034 puts trading, or 5x expected. Most active are Apr-25 72 puts and Apr-25 70 puts, with total ...

The Canada Border Services Agency has made another big drug bust at the Canada-U.S. border crossing in Coutts. CBSA said a 26-year-old Calgary man was arrested on March 8, after border agents ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence ...

AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and up to $575 million contingent on milestones. EsoBiotec's ENaBL platform ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...